What if I asked you to take 3/4 of the stomach, which is the size of a football, through a hole smaller than a dime. You would think I'm crazy. Have I lost my mind.What What am I talking about. Am I a magician. Am I pulling like a rabbit out of a hat or something like that.And that's actually what I thought 25 years ago when I started surgical residency. At that time you did a lot of surgeries with open abdominal incisions. You did laparottoies for traumas. You did laparottoies for emergency surgery to save ...

Company Overview - SS Innovations International, Inc. is a developer of innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [3] - The company is headquartered in India and plans to expand its global presence with user-friendly and cost-effective surgical robotic solutions [3] Recent Developments - The first robotic cardiac surgery in the Americas was successfully performed using the SSi Mantra 3 surgical robotic system on June 8, 2025, by Dr. Juan Zuniga in Guayaquil, Ecuador [1] - The procedure involved a robotic Atrial Septal Defect closure, which repairs a hole between the upper two chambers of the heart [1] Technology Features - The SSi Mantra surgical robotic system is a modular, multi-arm system featuring advanced technology such as 3 to 5 robotic arms, a 3D 4K monitor, and a touch panel for patient information [4] - It utilizes over 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery [4] - The system has been clinically validated in India for over 100 different types of surgical procedures [4] Surgical Experience - Dr. Zuniga reported that the SSi Mantra system was easy to handle, resulting in effective outcomes and faster recovery for patients due to its minimally invasive nature [2] - The precision of the robotic system enhances the surgeon's confidence in performing sutures and tissue manipulation [2] Hospital Adoption - Interhospital in Guayaquil is the first hospital in South America to install the SSi Mantra system and has utilized it for various complex surgical procedures since its installation [2]

Summary of Procept BioRobotics (PRCT) FY Conference Call - June 04, 2025 Company Overview - Procept BioRobotics is a surgical robotic company aiming to become a global leader in urology [3][4] - The company focuses on treating Benign Prostatic Hyperplasia (BPH), a condition affecting a significant portion of the male population [5] Industry Insights - BPH affects one in two men aged 50-60, with 40 million men in the U.S. suffering from this condition [5] - There is a large unmet clinical need, with only 12 million of the 40 million men under medical management [6] - The majority of men avoid surgical options due to side effects associated with current treatments [6][7] Product and Technology - Aquablation therapy is designed to address the unmet clinical need for BPH treatment, effective for all prostate sizes and shapes [6][9] - The technology utilizes an automated water jet, avoiding unnecessary damage to surrounding tissue [9] - Clinical studies show that aquablation has superior safety outcomes compared to traditional resective procedures like TURP [11][12] Market Access and Reimbursement - Full Medicare coverage is available for aquablation, with 95% of eligible patients having access to the treatment [15] - The facility payment for aquablation is just over $9,200, with expectations for reimbursement to align with other resective procedures [36][37] Financial Performance - The company reported a revenue of $69.2 million for the first quarter, a 55% year-over-year growth [22] - The installed base in the U.S. reached 547 systems, with significant international revenue growth, particularly in the U.K. and Japan [23][24] - Revenue guidance for 2025 is set at $323 million, with an expected growth rate of 63% to 64.5% [24] Future Opportunities - Procept is exploring the use of aquablation for prostate cancer treatment, addressing a significant unmet clinical need [16][18] - There are over 3 million men in the U.S. with prostate cancer, with 300,000 new cases annually [16] - The company is conducting clinical studies to demonstrate the safety and efficacy of aquablation in prostate cancer patients [19][22] Challenges and Execution - The company is focused on surgeon retention and increasing procedure volumes, with over 30,000 cases performed in the U.S. last year [32][33] - The transition from Category III to Category I reimbursement codes is a key milestone, expected to simplify pre-authorization processes [36][39] Conclusion - Procept BioRobotics is positioned to capitalize on the growing demand for effective BPH and prostate cancer treatments through innovative technology and strong clinical data [44]

Core Insights - SS Innovations International, Inc. reported record quarterly revenue of $5.1 million for Q1 2025, a 40.8% increase from $3.6 million in Q1 2024, driven by higher sales of the SSi Mantra 3 surgical robotic system [4][6] - The company plans to submit a De Novo application to the FDA for the SSi Mantra 3 by the end of July 2025, aiming for approval in the U.S. and European markets [4][6] Financial Performance - Revenue increased by 40.8% to $5.1 million from $3.6 million in Q1 2024 [6] - Gross margin improved by 121 basis points to 21.23% from 20.02% in Q1 2024 [6] - Gross profit rose by 49.3% to $1.1 million from $0.7 million in Q1 2024 [6] - Net loss decreased to $5.7 million, or $(0.03) per diluted share, compared to a net loss of $9.8 million, or $(0.06) per diluted share, in Q1 2024 [6] Business Highlights - SSi Mantra installations totaled 15, a 66.7% increase from 9 installations in Q1 2024 [6] - Cumulative installed base of SSi Mantra reached 78, with cumulative surgeries totaling 3,568 [6][8] - Significant growth in instrument sales (302.7%) and warranty sales (1,202.3%) compared to Q1 2024 [8] Strategic Developments - The company uplisted to The Nasdaq Capital Market on April 25, 2025, marking a milestone for global expansion [3][4] - Plans to expand market presence beyond the seven countries where the SSi Mantra has been cleared, focusing on the EU and U.S. [4] Product Innovations - The SSi Mantra 3 surgical robotic system enabled the world's first robotic cardiac telesurgery [7] - The system received regulatory approvals in the Philippines and Ukraine, enhancing its market potential [7]